CanSino Biologics Inc. (HKG:6185)
Hong Kong · Delayed Price · Currency is HKD 29.34
-1.06 (-3.49%)
May 12, 2026, 4:08 PM HKT
CanSino Biologics Employees
CanSino Biologics had 1,134 employees as of December 31, 2025. The number of employees increased by 29 or 2.62% compared to the previous year.
Employees
1,134
Change
29
Growth
2.62%
Revenue / Employee
1.12M HKD
Profits / Employee
-1.01K HKD
Market Cap
12.95B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,134 | 29 | 2.62% |
| Jun 30, 2025 | 1,115 | - | - |
| Dec 31, 2024 | 1,105 | -389 | -26.04% |
| Dec 31, 2023 | 1,494 | -797 | -34.79% |
| Dec 31, 2022 | 2,291 | 345 | 17.73% |
| Dec 31, 2021 | 1,946 | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Employee RankingsCanSino Biologics News
- 3 months ago - CanSinoBIO at WGS 2026: Accelerating Global Access to Innovative Vaccines - PRNewsWire
- 3 years ago - World-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen® and CanSinoBIO, First Public Booster Immunization in China. - Business Wire
- 4 years ago - China's CanSinoBIO H1 revenue drops on weaker COVID shot demand - Reuters
- 4 years ago - CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing - PRNewsWire
- 4 years ago - CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research - PRNewsWire
- 4 years ago - CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China - PRNewsWire
- 4 years ago - CanSinoBIO's Convidecia™ Approved as Heterologous Booster in Malaysia and Indonesia - PRNewsWire
- 4 years ago - Latest Study Shows Advantages of CanSinoBIO's Convidecia™ as Heterologous Booster against Omicron Variant - PRNewsWire